Search

CN-122000056-A - Application of plasma CXCL16 as marker in assessing pulmonary arterial hypertension

CN122000056ACN 122000056 ACN122000056 ACN 122000056ACN-122000056-A

Abstract

The application discloses an application of plasma CXCL16 as a marker in assessing pulmonary hypertension, which comprises the following specific steps of S1, processing a plasma sample, S2, detecting the concentration of CXCL16 in the plasma by an ELISA method, S3, comparing the concentration of CXCL16 with a healthy control group, a CTEPD pulmonary artery-free high-pressure group and other pulmonary artery high-pressure groups, and S4, correlating the concentration of CXCL16 with the change of hemodynamic parameters before and after BPA treatment.

Inventors

  • LIU MIN
  • LIU JIXIANG
  • YU WEI
  • LI FAJIU

Assignees

  • 江汉大学附属医院(武汉市第六医院)

Dates

Publication Date
20260508
Application Date
20260126

Claims (7)

  1. 1. Use of plasma CXCL16 as a marker for assessing pulmonary arterial hypertension, comprising the specific steps of: s1, treating a plasma sample; S2, detecting the concentration of CXCL16 in blood plasma by using an ELISA method; s3, comparing CXCL16 concentration with a healthy control group, CTEPD pulmonary artery free high-pressure group and other types of pulmonary artery high-pressure groups; s4, correlating CXCL16 concentration with hemodynamic parameter changes before and after BPA treatment.
  2. 2. The use of plasma CXCL16 as a marker according to claim 1 for assessing pulmonary arterial hypertension, wherein the treatment of the plasma sample in S1 is specifically performed by placing the plasma sample in EDTA anticoagulation tube, centrifuging the plasma, and preserving at-80 ℃.
  3. 3. Use of plasma CXCL16 according to claim 2 as a marker for assessing pulmonary arterial hypertension, characterized in that the parameters of centrifugation of plasma are such that the upper plasma is separated by centrifugation at 3000rpm for 10min at 4 ℃.
  4. 4. The use of plasma CXCL16 as a marker in the assessment of pulmonary arterial hypertension according to claim 1, wherein the concentration of CXCL16 in plasma is detected in S2 by the following steps: S21, diluting the capture antibody with a coating buffer solution for fixation; s22, discarding the coating liquid, and reducing nonspecific binding by using a blocking liquid; s23, sampling a plasma sample and a standard substance, and synchronously detecting; S24, diluting the HRP-coupled detection antibody by using a sample diluent; S25, discarding the detection antibody, and performing a color reaction; S26, substituting the corrected OD value of the sample into a standard curve equation, and calculating the CXCL16 concentration of the diluted sample.
  5. 5. The use of plasma CXCL16 as a marker according to claim 4 for assessing pulmonary arterial hypertension, wherein the specific formula of the standard curve equation is as follows: ; Wherein: in order to correct the post-calibration OD value, For CXCL16 concentration (pg/mL), a, b, c, d is a 4PL fitting parameter.
  6. 6. The use of plasma CXCL16 according to claim 1 as a marker for assessing pulmonary hypertension, wherein the criteria for the healthy control group, the CTEPD pulmonary hypertension-free group and the other type of pulmonary hypertension group in S3 are as follows: healthy controls, no chronic thromboembolic related disease, no pulmonary arterial hypertension (PH) and other chronic diseases that clearly affect the angiogenic or inflammatory pathways, plasma CXCL16 levels as a normal reference baseline; CTEPD pulmonary artery free high pressure group, after at least 3 months of therapeutic anticoagulation, there is chronic and organized thrombus in pulmonary artery, there is continuous perfusion defect and there is dyspnea, and average pulmonary artery pressure (mPAP) is less than or equal to 20mmHg in resting state as determined by Right Heart Catheterization (RHC) Other types of pulmonary arterial hypertension groups, measured by RHC, have average pulmonary arterial pressure (mPAP) of >20mmHg, pulmonary capillary wedge pressure (PAWP) of less than or equal to 15mmHg and Pulmonary Vascular Resistance (PVR) of >2Wood Units (WU) and meet the general diagnostic standard of PH in ERS/ESC guidelines.
  7. 7. The use of plasma CXCL16 according to claim 1 as a marker for assessing pulmonary hypertension, characterized in that in S4 the hemodynamic parameter variation correlation comprises the following specific steps: S41, grouping according to CXCL16 concentration median, namely taking the CTEPH patient CXCL16 expression median (10.54 ng/mL) in the verification queue as a cut-off value, and dividing into a high CXCL16 group and a low CXCL16 group; grouping according to BPA treatment response, namely classifying BPA responders and BPA non-responders according to RHC results 3 months after operation; s42, calculating the change value and the change percentage of the postoperative hemodynamic parameters of each group of patients relative to the change value and the change percentage of the postoperative hemodynamic parameters of each group of patients; s43, comparing the differences among groups, namely comparing the parameter variation differences among the groups with high/low CXCL16 and between BPA responders and BPA non responders by adopting an independent sample t test or Wilcoxon rank sum test; Calculating a Pearson correlation coefficient (r), and evaluating the correlation between CXCL16 concentration and the hemodynamic parameter; multivariate regression analysis, adjusting gender, age, total number of dilated vessels, NT-proBNP confounding factors, verifying if CXCL16 is an independent influencing factor for BPA treatment response (parameter variation).

Description

Application of plasma CXCL16 as marker in assessing pulmonary arterial hypertension Technical Field The invention belongs to the technical field of biomedical detection, and particularly relates to application of plasma CXCL16 serving as a marker in pulmonary arterial hypertension evaluation. Background Chronic thromboembolic pulmonary arterial hypertension (CTEPH) is a progressive disease characterized by thrombolytic defects, pulmonary artery occlusion, and secondary vascular lesions. The pathological mechanism is complex, thrombus stays in pulmonary artery for a long time and is organized, pulmonary Vascular Resistance (PVR) is continuously increased, and finally, right heart overload and progressive right heart failure are caused, so that the life health of a patient is seriously threatened. In clinical practice, early identification of CTEPH presents significant challenges. On the one hand, the disease symptoms are highly nonspecific, the early stage of the patients usually show common symptoms such as short breath and hypodynamia after activities and are easy to confuse with other diseases such as respiratory diseases and heart failure, and on the other hand, the clinical application of conventional screening means such as pulmonary ventilation/perfusion (V/Q) scanning is limited, so that the full coverage of high-risk groups is difficult to realize, and most patients are in middle and late stages of the diseases when they are diagnosed, and the optimal treatment time is missed. Currently, right Heart Catheterization (RHC) and pulmonary angiography are still "gold standards" for diagnosing CTEPH. The examination needs to send the catheter into the parts of the right atrium, the right ventricle, the pulmonary artery and the like through the puncture vein, and directly measures the key parameters such as hemodynamic index, blood oxygen saturation, cardiac output and the like, thereby providing a direct basis for disease diagnosis and disease assessment. However, the invasive operation characteristics have obvious defects that potential risks such as puncture wound, infection and bleeding are brought to patients, the potential risks are limited by equipment conditions and operation technology, the potential risks are difficult to popularize in basic medical institutions, the potential risks are not suitable for large-scale crowd screening, the medical cost is high, and the diagnosis and treatment experience of patients is poor. From the pathogenesis of the disease, inflammatory response and angiogenesis abnormality play a key role in the pathological process of CTEPH, and the interaction of the two together drive the development of thrombosis, vascular remodeling and pulmonary arterial hypertension. However, in the current clinical practice, there is still a lack of specific, high-sensitivity plasma protein biomarkers related to angiogenesis, and early diagnosis, differential diagnosis and treatment response assessment of diseases cannot be achieved by non-invasive means. The existing diagnosis system excessively depends on invasive examination, and is difficult to meet urgent clinical requirements for accurate and noninvasive diagnosis and treatment of CTEPH. Disclosure of Invention The invention aims to provide an application of plasma CXCL16 serving as a marker in assessing pulmonary hypertension, so as to solve the problems that the current diagnosis proposed in the background art mainly depends on right heart catheter examination (RHC) and pulmonary angiography, a puncture vein is needed to send a catheter into parts such as a right atrium, a right ventricle and a pulmonary artery, indexes such as hemodynamics, blood oxygen saturation and cardiac output are measured, and clinical accurate and noninvasive diagnosis and treatment of CTEPH are difficult to meet. In order to achieve the above purpose, the invention provides the following technical scheme that the application of plasma CXCL16 serving as a marker in assessing pulmonary hypertension comprises the following specific steps: s1, treating a plasma sample; S2, detecting the concentration of CXCL16 in blood plasma by using an ELISA method; s3, comparing CXCL16 concentration with a healthy control group, CTEPD pulmonary artery free high-pressure group and other types of pulmonary artery high-pressure groups; s4, correlating CXCL16 concentration with hemodynamic parameter changes before and after BPA treatment. Preferably, the plasma sample is treated in the step S1, specifically, the plasma sample is placed in an EDTA anticoagulation tube, and the plasma is centrifugally separated and stored at-80 ℃ for standby. Preferably, the parameters of the centrifugation of the plasma are such that the upper plasma is separated by centrifugation at 3000rpm for 10min at 4 ℃. Preferably, the concentration of CXCL16 in plasma is detected in S2 as follows: S21, diluting the capture antibody with a coating buffer solution for fixation; s22, discarding the coatin